1.
|
11 p, 959.0 KB |
Outcome of liver cancer patients with SARS-CoV-2 infection : An International, Multicentre, Cohort Study
/
Muñoz-Martínez, S (Hospital Clínic i Provincial de Barcelona) ;
Sapena, Victor (Hospital Clínic i Provincial de Barcelona) ;
Forner, Alejandro (Hospital Clínic i Provincial de Barcelona) ;
Bruix, Jordi (Hospital Clínic i Provincial de Barcelona) ;
Sanduzzi Zamparelli, Marco (Hospital Clínic i Provincial de Barcelona) ;
Ríos, José (Hospital Clínic i Provincial de Barcelona) ;
Bouattour, Mohamed (Hôpital Beaujon) ;
El-Kassas, Mohamed (Helwan University) ;
Leal, Cassia R. G. (Hospital Federal do Servidores do Estado) ;
Mocan, Tudor ("Octavian Fodor" Institute for Gastroenterology and Hepatology) ;
Nault, Jean-Charles (Université de Paris) ;
Alves, Rogerio C. P. (Bp Beneficência Portuguesa de São Paulo) ;
Reeves, Helen L. (Newcastle University Translational and Clinical Research Institute) ;
Da Fonseca, Leonardo G (University of Sao Paulo School of Medicine) ;
García-Juárez, Ignacio (National Institute of Medical Sciences and Nutrition Salvador Zubirán) ;
Pinato, David J. (Imperial College London) ;
Varela Calvo, Maria (Hospital Universitario Central de Asturias) ;
Alqahtani, Saleh A. (King Faisal Specialist Hospital & Research Center) ;
Alvares-da-Silva, Mario R. (Universidade Federal do Rio Grande do Sul) ;
Bandi, Juan C. (Hospital Italiano) ;
Rimassa, Lorenza (Humanitas Cancer Center) ;
Lozano, Mar (Hospital Universitario Infanta Leonor) ;
González Santiago, Jesús M. (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ;
Tacke, Frank (Campus Virchow-Klinikum and Campus Charité Mitte) ;
Sala, Margarita (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ;
Anders, María (Hepatología) ;
Lachenmayer, Anja (Bern University Hospital) ;
Piñero, Federico (Hospital Universitario Austral) ;
França, Alex (Federal University of Sergipe) ;
Guarino, Maria (University of Naples Federico II) ;
Elvevi, Alessandra (Bicocca School of Medicine) ;
Cabibbo, Giuseppe (University of Palermo) ;
Peck-Radosavljevic, Markus (Klinikum Klagenfurt am Wörthersee) ;
Rojas, Ángela (Universidad de Sevilla) ;
Vergara, Mercedes (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Braconi, Chiara (University of Glasgow) ;
Pascual, Sonia (HGU Dr. Balmis) ;
Perelló, Christie (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Mello, Vivianne (AMO CLINIC) ;
Rodríguez-Lope, Carlos (IDIVAL) ;
Acevedo, Juan (University Hospitals Plymouth NHS Trust (Regne Unit)) ;
Villani, Rosanna (Department of Medical and Surgical Sciences) ;
Hollande, Clemence (Hôpital Beaujon) ;
Vilgrain, Valérie (Hôpital Beaujon) ;
Tawheed, Ahmed (Helwan University) ;
Ferguson Theodoro, Carmem (Universidade Federal Fluminense) ;
Sparchez, Zeno (University of Medicine and Pharmacy) ;
Blaise, Lorraine (Université de Paris) ;
Viera-Alves, Daniele E. (Bp Beneficência Portuguesa de São Paulo) ;
Watson, Robyn (Newcastle University Translational and Clinical Research Institute) ;
Carrilho, Flair J. (University of Sao Paulo School of Medicine) ;
Moctezuma-Velázquez, Carlos (National Institute of Medical Sciences and Nutrition Salvador Zubirán) ;
D'Alessio, Antonio (Humanitas University) ;
Iavarone, Massimo (Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico) ;
Reig, María (Hospital Clínic i Provincial de Barcelona) ;
Universitat Autònoma de Barcelona
Information about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with liver cancer is lacking. This study characterizes the outcomes and mortality risk in this population. [...]
2022 - 10.1111/liv.15320
Liver International, Vol. 42 (june 2022) , p. 1891-1901
|
|
2.
|
9 p, 1.7 MB |
KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer
/
Sclafani, Francesco (The Royal Marsden NHS Foundation Trust) ;
Chau, Ian (The Royal Marsden NHS Foundation Trust) ;
Cunningham, David (The Royal Marsden NHS Foundation Trust) ;
Hahne, Jens Claus (The Institute of Cancer Research) ;
Vlachogiannis, George (The Institute of Cancer Research) ;
Eltahir, Zakaria (The Royal Marsden NHS Foundation Trust) ;
Lampis, Andrea (The Institute of Cancer Research) ;
Braconi, Chiara (The Institute of Cancer Research) ;
Kalaitzaki, Eleftheria (The Royal Marsden NHS Foundation Trust) ;
De Castro, David Gonzalez (The Royal Marsden NHS Foundation Trust) ;
Wotherspoon, Andrew (The Royal Marsden NHS Foundation Trust) ;
Capdevila Castillón, Jaume (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Glimelius, Bengt (University of Uppsala) ;
Tarazona, Noelia (Universitat de València) ;
Begum, Ruwaida (The Royal Marsden NHS Foundation Trust) ;
Lote, Hazel (The Institute of Cancer Research) ;
Hulkki Wilson, Sanna (The Royal Marsden NHS Foundation Trust) ;
Mentrasti, Giulia (The Institute of Cancer Research) ;
Brown, Gina (The Royal Marsden NHS Foundation Trust) ;
Tait, Diana (The Royal Marsden NHS Foundation Trust) ;
Oates, Jacqueline (The Royal Marsden NHS Foundation Trust) ;
Valeri, Nicola (The Institute of Cancer Research) ;
Universitat Autònoma de Barcelona
There are limited data on circulating, cell-free, tumour (ct)DNA analysis in locally advanced rectal cancer (LARC). Digital droplet (dd)PCR was used to investigate KRAS/BRAF mutations in ctDNA from baseline blood samples of 97 LARC patients who were treated with CAPOX followed by chemoradiotherapy, surgery and adjuvant CAPOX ± cetuximab in a randomised phase II trial. [...]
2018 - 10.1038/s41598-018-19212-5
Scientific reports, Vol. 8 (january 2018)
|
|
3.
|
6 p, 1.4 MB |
Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients
/
Sclafani, Francesco (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
Chau, Ian (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
Cunningham, David (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
Lampis, Andrea (The Institute of Cancer Research. Department of Molecular Pathology) ;
Hahne, Jens Claus (The Institute of Cancer Research. Department of Molecular Pathology) ;
Ghidini, Michele (The Institute of Cancer Research. Department of Molecular Pathology) ;
Lote, Hazel (The Institute of Cancer Research. Department of Molecular Pathology) ;
Zito, Domenico (The Institute of Cancer Research. Department of Molecular Pathology) ;
Tabernero, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Glimelius, Bengt (University of Uppsala. Genetics and Pathology, Experimental and Clinical Oncology. Department of Immunology) ;
Cervantes, Andrés (University of Valencia. Biomedical Research Institute INCLIVA. Department of Haematology and Medical Oncology) ;
Begum, Ruwaida (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
De Castro, David Gonzalez (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
Wilson, Sanna Hulkki (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
Peckitt, Clare (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
Eltahir, Zakaria (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
Wotherspoon, Andrew (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
Tait, Diana (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
Brown, Gina (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
Oates, Jacqueline (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
Braconi, Chiara (The Institute of Cancer Research. Department of Cancer Therapeutics) ;
Valeri, Nicola (The Institute of Cancer Research. Department of Molecular Pathology) ;
Universitat Autònoma de Barcelona
Analysis of a polymorphism in mature microRNA-608 (rs4919510) in rectal cancer patients enrolled in a randomized phase II clinical trial identified patient subpopulations who might benefit from the use of an intensified neo-adjuvant treatment strategy with Cetuximab. [...]
2016 - 10.1093/carcin/bgw073
Carcinogenesis, Vol. 37 (july 2016) , p. 852-857
|
|
4.
|
6 p, 225.1 KB |
Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer : results of the EXPERT-C trial
/
Sclafani, Francesco (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
Chau, Ian (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
Cunningham, David (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
Peckitt, C. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
Lampis, Andrea (The Institute of Cancer Research. Division of Molecular Pathology (UK)) ;
Hahne, Jens Claus (The Institute of Cancer Research. Division of Molecular Pathology (UK)) ;
Braconi, Chiara (The Institute of Cancer Research. Division of Cancer Therapeutics (UK)) ;
Tabernero, Josep (Hospital Universitari Vall d'Hebron) ;
Glimelius, B. (University of Uppsala. Department of Immunology, Genetics and Pathology (Sweden)) ;
Cervantes, Andrés (Universitat de València. Departament d'Hematologia i Oncologia Mèdica) ;
Begum, Ruwaida (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
González De Castro, David (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
Hulkki Wilson, Sanna (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
Eltahir, Zakaria (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
Wotherspoon, Andrew (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
Tait, D. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
Brown, Gina (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
Oates, J. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
Valeri, Nicola (The Institute of Cancer Research. Division of Molecular Pathology (UK)) ;
Universitat Autònoma de Barcelona
Lethal-7 (let-7) is a tumour suppressor miRNA which acts by down-regulating several oncogenes including KRAS. A single-nucleotide polymorphism (rs61764370, T > G base substitution) in the let-7 complementary site 6 (LCS-6) of KRAS mRNA has been shown to predict prognosis in early-stage colorectal cancer (CRC) and benefit from anti-epidermal growth factor receptor monoclonal antibodies in metastatic CRC. [...]
2015 - 10.1093/annonc/mdv285
Annals of oncology, Vol. 26, Issue 9 (September 2015) , p. 1936-1941
|
|